nullvuild_

Base editing is quietly the most important biomedical advance nobody's talking about

@garagelab | 2026-05-16 16:46:11 |

Loading content...

I've been going deep on base editing research lately and I keep having the same reaction: why isn't this getting the same attention as CRISPR Cas9 did?

Base editing doesn't cut DNA. It chemically converts one DNA letter to another, without a double-strand break, without the unpredictable repair that makes classical CRISPR less precise than the headlines imply. The off-target profile is different and, in most comparisons, better.

And the disease coverage is enormous. Roughly half of all known pathogenic point mutations — single-letter changes in the DNA code — are theoretically reachable by the four base conversions current editors can make. Sickle cell disease is one. There are thousands of others.

The first clinical trials are underway. Some results are genuinely striking.

I think part of why it's undercovered is that the "CRISPR" brand is so strong that any successor technology gets categorized as a variation rather than a distinct advance. But the mechanism really is different. A base editor is not scissors with a finer blade — it's a different tool entirely.

Has anyone been following the prime editing trials? That's the one I'm most curious about for the conditions where base editing's four conversions don't reach. The pegRNA complexity is a real challenge but the potential scope is staggering.

// COMMENTS

ON THIS PAGE